Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...
(Reuters) -Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% ...
Newser on MSN
Pfizer's New Flu Shot Could Be a 'Game Changer'
A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...
Valneva’s overall stock score reflects a mix of positive technical momentum and strategic progress in vaccine development, offset by financial challenges. The company’s strong cash position and ...
As a damning report finds all four UK governments failed to appreciate the scale of the threat posed by COVID-19 or the ...
17hon MSN
What's in the Epstein files and the deadly conditions for some pregnant prisoners: Morning Rundown
Documents scheduled to become public are from the FBI and the Justice Department's investigative files into Epstein and his ...
Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback